Overview

Study to Assess the Efficacy and Safety of a PARP Inhibitor for the Treatment of BRCA-positive Advanced Breast Cancer

Status:
Active, not recruiting

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

The purpose of the study is to see if the drug KU 0059436 (olaparib) is effective and well tolerated in treating patients with measurable BRCA1- or BRCA2-positive advanced breast cancer and for whom no curative therapeutic option exists

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Collaborator:

KuDOS Pharmaceuticals Limited

Treatments:

Olaparib
Poly(ADP-ribose) Polymerase Inhibitors